YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
Sponsor: Astellas Pharma Inc
Terminated
This trial was terminated. No reason was provided.
Listed as NCT00050297, this PHASE2 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Astellas Pharma Inc, it has been updated 6 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Astellas Pharma US, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Homburg, Germany , Bristol, United Kingdom , Brussels, Belgium , Bydgoszcz, Poland , Corunna, Spain , Dresden, Germany , Gdansk, Poland , Glasgow, United Kingdom , Jablonec nad Nisou, Czechia , Králové, Czechia and 9 more locations